BioCentury | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

...The CDK7 program is not Syros’ most advanced. The company’s SY-1425, an agonist of RARA...
...had $121.7 million in cash at June 30. Targets: CDK7 - Cyclin dependent kinase 7; RARA...
BioCentury | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

...patient. The eight patients in the cohort were positive for the retinoic acid receptor α (RARA...
...Product: Amnolake tamibarotene (SY-1425) Business: Cancer Molecular target: Retinoic acid receptor α (RARA) Description: Synthetic RARA...
...INNO-507, TM-411, TOS-80T, Z-208) American Society of Hematology ASH Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon regulatory factor 8 (IRF8) Retinoic acid receptor alpha (RARA...
BioCentury | Jan 19, 2018
Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

...acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA...
...from retinoid and anthracycline chemotherapy, and characterized by the presence of the t(15;17) translocation or PML-RARA...
...20, 2005 ). Trisenox is an arsenic trioxide that causes DNA fragmentation and damage to PML-RARA...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

...patients in all dosing groups Syros Pharmaceuticals Inc. (NASDAQ:SYRS) -27% $8.99 SY-1425, a synthetic retinoic acid receptor alpha (RARA...
BioCentury | Dec 15, 2017
Clinical News

Syros discontinues single agent tamibarotene

...single agent. The trial enrolled AML and MDS patients who were positive for the retinoic acid receptor alpha (RARA...
...Japan Product: Amnolake tamibarotene (SY-1425) (formerly AM-80) Business: Cancer Molecular target: Retinoic acid receptor alpha (RARA) Description: Synthetic RARA...
...Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon regulatory factor 8 (IRF8) Retinoic acid receptor alpha (RARA...
BioCentury | Dec 11, 2017
Clinical News

Syros falls on Phase II AML, MDS data

...single agent. The trial enrolled AML and MDS patients who were positive for the retinoic acid receptor alpha (RARA...
...MDS patients. Syros has exclusive rights from TMRC Co. Ltd. (Tokyo, Japan) to the synthetic RARA...
...Johnson azacitidine daratumumab Darzalex tamibarotene Vidaza American Society of Hematology Celgene Corp. Johnson & Johnson Syros Pharmaceuticals Inc. TMRC Co. Ltd. Interferon regulatory factor 8 (IRF8) Retinoic acid receptor alpha (RARA...
BioCentury | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

...two clinical programs that both indirectly target enhancers. Amnolake tamibarotene is a synthetic agonist of RARA...
...both programs’ targets were already on the radar for other cancers, Olson said Syros discovered RARA’s...
...on the results, Syros is testing Amnolake in AML and MDS subsets positive for specific RARA...
BioCentury | Oct 20, 2017
Clinical News

FDA grants Priority Review to Teva's Trisenox sNDA

...promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia- retinoic acid receptor alpha (PML-RARA...
...PML-RARA gene expression. Trisenox is an arsenic trioxide that causes DNA fragmentation and damage to PML-RARA...
...Tikva, Israel Product: Trisenox arsenic trioxide Business: Cancer Elizabeth S. Eaton Trisenox Teva Pharmaceutical Industries Ltd. Promyelocytic leukemia (PML) Retinoic acid receptor alpha (RARA) DNA...
BioCentury | Apr 21, 2017
Financial News

Syros, SteadyMed complete private placements

...MDS). Syros has exclusive rights from TMRC Co. Ltd. (Tokyo, Japan) to the synthetic retinoic acid receptor alpha (RARA...
...launch the prostacyclin analog treprostinil delivered via its subcutaneous PatchPump technology. Chris Lieu Amnolake tamibarotene Trevyent SteadyMed Ltd. Syros Pharmaceuticals Inc. Retinoic acid receptor alpha (RARA...
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...than cells from normal mice. In the mouse model, the synthetic retinoic acid receptor α (RARA...
Items per page:
1 - 10 of 30